Skip To Main Content
Flaherty KT on Muck Rack

Flaherty KT

As seen in: Nature, Oxford University Press (OUP), Oncology Central
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Flaherty KT’s profile

Articles by Flaherty KT

Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation

|
By Ascierto PA, Gogas HJ, Flaherty KT
| Oxford University Press (OUP)
The mitogen-activated protein kinase (MAPK) pathway plays a critical role in cellular signaling and contributes to the regulation of a variety of processes including cell proliferation, survival, differentiation, motility, and angiogenesis.1,2 The fundamental components of the pathway consist of the Ras small GTPases, which recruit and activate the downstream kinases RAF and MEK (MAP kinases) that in turn trigger the activation of the extracellular signal-regulated kinase (ERK) proteins.3...
Open in Who Shared Issue with article?

A plain language summary of the COLUMBUS study: encorafenib plus binimetinib for BRAF V600-mutant melanoma

|
By Flaherty KT, Jade Parker
| Oncology Central Verified
Our partnered journal Future Oncology recently published a plain language summary of publication summarizing the 5-year results from part 1 of the COLUMBUS clinical study, which looked at the combination treatment of encorafenib plus binimetinib for BRAF V600-mutant melanoma patients. Gain access to the full paper here. Abstract What is this summary about?
Open in Who Shared Issue with article?

The NCI-MATCH trial: lessons for precision oncology

|
By O'Dwyer PJ, Gray RJ, Flaherty KT, Chen AP
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (616) Issue with article?

COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF - PubMed

|
By Flaherty KT, Gogas HJ, Pietro AD, Cantey-Kiser J
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (601) Issue with article?

Molecular testing for <i>BRAF</i> mutations to inform melanoma treatment decisions: a move toward precision medicine

|
By Siegel RL, Miller KD, Luke JJ, Flaherty KT
| Nature Verified
After a preliminary diagnosis of stage III or IV metastatic melanoma, the lesion(s) should be evaluated for BRAF mutational status.40 Cutaneous lesions suspected of being melanoma are typically resected with a wide margin, providing the entire lesion and its margins for analysis. Radiologically detected lesions within internal organs are sampled by core-needle and/or fine-needle aspiration biopsy. The postsurgical processing of surgical resections vs fine-needle aspirates is slightly different.
Open in Who Shared Issue with article?
Show More